The current study suggests that bevacizumab suppresses fluid retention essentially by blocking vascular permeability caused by VEGF, which consequently inhibits the growth of HHV8‐unrelated ELBCL because body cavity effusions provide a sanctuary for this type of lymphoma that affords a survival advantage. This evidence concerns the gene VEGFA and lymphoma.